Z. Ghazoui

发表

Community assessment of cancer drug combination screens identifies strategies for synergy prediction

Tin Chi Nguyen, Robert M. Vogel, M. Zaslavskiy, 2017, bioRxiv.

A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination prediction

Robert M. Vogel, M. Zaslavskiy, Y. Guan, 2018 .

ESR 1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6 q 25 . 1

Mitch Dowsett, Helen Anderson, M. Dowsett, 2012 .

ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1

Mitch Dowsett, Helen Anderson, M. Dowsett, 2011, PLoS genetics.

Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance

M. Dowsett, J. Salter, Z. Ghazoui, 2013, Clinical Cancer Research.

Expression of estrogen responsive genes in breast cancers correlates with plasma estradiol levels in postmenopausal women.

M. Ellis, M. Dowsett, Z. Ghazoui, 2009 .

Cancer Therapy: Clinical Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer

M. Dowsett, A. Harris, J. Salter, 2011 .

An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition

M. Dowsett, S. Johnston, Z. Ghazoui, 2011, Steroids.

Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

A. Bode, Pengyuan Liu, Yan Lu, 2013, Cancer Prevention Research.

Personalized Medicine and Imaging Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

M. Dowsett, Z. Ghazoui, R. A’Hern, 2014 .

Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer

M. Dowsett, Z. Ghazoui, S. Pancholi, 2012, Breast Cancer Research.

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.

G. Mills, M. Dowsett, J. Balko, 2011, Cancer discovery.

Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer

M. Dowsett, A. Harris, J. Salter, 2011, Clinical Cancer Research.

ERa-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

G. Mills, M. Dowsett, J. Balko, 2011 .

Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

G. Mills, M. Dowsett, J. Balko, 2011 .

Rare variant contribution to human disease in 281,104 UK Biobank exomes

Sri V. V. Deevi, Katherine R. Smith, B. Linghu, 2021, Nature.

A Common Genomic Framework for a Diverse Assembly of Plasmids in the Symbiotic Nitrogen Fixing Bacteria

Georgios S. Vernikos, Lisa C. Crossman, J. Parkhill, 2008, PloS one.

The genome of Rhizobium leguminosarum has recognizable core and accessory components

Lisa C. Crossman, M. Quail, K. Mungall, 2006, Genome Biology.

Defining actionable mutations for oncology therapeutic development

Jonathan R. Dry, Zhongwu Lai, J. Carl Barrett, 2016, Nature Reviews Cancer.

Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.

C. Perou, M. Ellis, M. Dowsett, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.

M. Dowsett, J. Reis-Filho, J. Salter, 2011, Endocrine-related cancer.

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer

M. Dowsett, J. Reis-Filho, Z. Ghazoui, 2015, Breast Cancer Research.

Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen

Robert M. Vogel, M. Zaslavskiy, Y. Guan, 2019, Nature Communications.

Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.

Mitch Dowsett, Helen Anderson, Roger A'Hern, 2011, Journal of the National Cancer Institute. Monographs.

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo

M. Dowsett, H. Lane, S. Johnston, 2012, Breast Cancer Research.

Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor–Positive Breast Cancer and Their Relationship with Antiproliferative Response

M. Zvelebil, M. Dowsett, Z. Ghazoui, 2014, Clinical Cancer Research.

Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen

Amir K. Foroushani, Yuanfang Guan, Jaewoo Kang, 2019, Nature Communications.

Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer

M. Dowsett, Z. Ghazoui, R. A’Hern, 2014, Clinical Cancer Research.

A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance

Yu Shyr, Gordon B Mills, Mitch Dowsett, 2011, Clinical Cancer Research.

The Effects of Neoadjuvant Anastrozole and Tamoxifen on Circulating Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor 1 in Breast Cancer

M. Dowsett, Z. Ghazoui, I. Smith, 2008, Clinical Cancer Research.

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers

Mitch Dowsett, M. Dowsett, Z. Ghazoui, 2014, Breast Cancer Research.

Abstract S2-5: Molecular Profiling of Aromatase Inhibitor-Treated Post-Menopausal Breast Tumours Identifies Determinants of Response

M. Dowsett, Z. Ghazoui, I. Smith, 2010 .

Association between breast cancer subtypes and response to neoadjuvant anastrozole

C. Perou, M. Dowsett, J. Parker, 2011, Steroids.

Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.

A. Matakidou, L. Siu, Z. Ghazoui, 2020 .

Abstract 2920: Experimental and clinical studies reveal the PDGF/Abl pathway as a novel therapeutic target in endocrine-resistant breast cancer

M. Dowsett, Z. Ghazoui, A. Lykkesfeldt, 2010 .